AML in Adults

AbstractAML is a malignancy of hematopoietic immature precursors (myeloblasts) that accumulate in the BM at the expense of their normal counterparts. AML is increasingly being recognized as a heterogenous malignancy based on distinct disease biology and underlying cytogenetic and molecular profiles. These profiles and measurable residual disease after induction therapy direct post-remission strategies in a risk-adapated approach, which also includes the assessment of the risk of treatment-related mortality. In primary refractory AML, allo-HSCT remains a curative treatment option in fit patients. Allo-HSCT in acute promyelocytic leukemia is only recommended for specific cases, particularly when not in moleculair remission after treatment for first relapse.